Knoll Capital Management’s BioXcel Therapeutics BTAI Stock Holding History

Knoll Capital Management’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,750	Closed	-$152K	–	35
2023 Q3	$152K	Buy	3,750 +1,875	+100%	+$190K	0.16%	36
2023 Q2	$200K	Buy	+1,875	New	+$624K	0.24%	27
2022 Q4	–	Sell	-1,250	Closed	-$236K	–	25
2022 Q3	$236K	Hold	1,250	–	–	0.14%	29
2022 Q2	$92K	Hold	1,250	–	–	0.05%	37
2022 Q1	$418K	Hold	1,250	–	–	0.26%	32
2021 Q4	$407K	Hold	1,250	–	–	0.22%	28
2021 Q3	$607K	Hold	1,250	–	–	0.3%	25
2021 Q2	$581K	Hold	1,250	–	–	0.3%	30
2021 Q1	$863K	Hold	1,250	–	–	0.56%	26
2020 Q4	$924K	Hold	1,250	–	–	0.63%	18
2020 Q3	$867K	Hold	1,250	–	–	0.71%	16
2020 Q2	$1.07M	Hold	1,250	–	–	0.62%	17
2020 Q1	$447K	Buy	+1,250	New	+$449K	0.42%	18

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Knoll Capital Management's BTAI Position: Q4 2023 in Review

Knoll Capital Management sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 3,750 shares — an estimated $152K sold.

Knoll Capital Management first reported a position in BTAI in Q1 2020 and held it in 13 quarters. The position peaked at $1.07M in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Knoll Capital Management reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Knoll Capital Management sold 3,750 BioXcel Therapeutics shares in Q4 2023, an estimated $152K.
Knoll Capital Management first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 13 quarters.
Knoll Capital Management's BioXcel Therapeutics position peaked at $1.07M in Q2 2020.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Knoll Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.